6-Quinoxalinamine

It acts as the core quinoxaline structure that is brominated and coupled with an imidazoline moiety (such as N-acetyl ethylene urea or imidazoline sulfonic acid) to form the final compound, with high-yield, safe, and efficient processes often involving bromination using dibromohydantoin. 6-Quinoxalinamine (specifically 5-bromo-6-quinoxalinamine) is a key intermediate in the synthesis of Brimonidine tartrate, a glaucoma medication.